Prospective randomized study of N‐acetylcysteine, fenoldopam, and saline for prevention of radiocontrast‐induced nephropathy
Citations Over TimeTop 1% of 2002 papers
Abstract
The objective of this study was to compare the efficacy of N-acetylcysteine (NAC), fenoldopam, and saline in preventing radiocontrast-induced nephropathy (RCIN) in high-risk patients undergoing cardiovascular procedures. We prospectively enrolled 123 patients who were scheduled for cardiovascular procedures and had a baseline creatinine > 1.6 mg/dl or creatinine clearance of 0.5 mg/dl after 48 hr. The incidence of RCIN was 17.7% in the NAC group, 15.3% in the saline group, and 15.7% in the fenoldopam group (P = 0.919). Of the 20 patients who developed RCIN, 2 required dialysis. Serum creatinine decreased after 48 hr (vs. baseline) in 38% patients in the NAC group, 18% in the fenoldopam group, and 15% in the saline group. In patients with chronic renal insufficiency, NAC or fenoldopam offered no additional benefit over hydration with saline in preventing RCIN.
Related Papers
- → The Pharmacology of Fenoldopam(1990)48 cited
- The role of the DA1 receptor agonist fenoldopam in the management of critically ill, transplant, and hypertensive patients.(2003)
- [Fenoldopam: potential clinical applications in heart surgery].(2001)
- → “Fenoldopam Prophylaxis” Works in Impending Acute Renal Failure: Recruiting the non-hemodynamic properties of fenoldopam?(2007)2 cited
- → Fenoldopam and Acute Kidney Injury: Is It Time to Turn the Page?(2016)